AbbVie Inc.
New York Stock Exchange•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Robert A. Michael CPA
- Full Time Employees
- 55,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 1 North Waukegan Road North Chicago IL United States of America 60064-6400
- IPO Date
- Jan 2, 2013
- CIK
- 0001551152
- Website
- abbvie.com
- Similar Companies
- Business
- AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Company News
AbbVie (ABBV) Surpasses Market Returns: Some Facts Worth Knowing
How Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?
Here's How to Play AbbVie Stock as it Reaches Golden Cross
3 No-Brainer Dividend Stocks to Buy In July
3 Dividend Growth Stocks to Buy and Hold
The Smartest Dividend Stocks to Buy With $300 Right Now
ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now?
A Sweet Spot Between Yield And Growth: The Best Balanced Dividend Growers For 2025
What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill
Glenmark Pharma jumps on unit's cancer licensing deal with AbbVie
AbbVie (ABBV) Laps the Stock Market: Here's Why
Why Is AbbVie Stock Trading Higher On Thursday?
Final Trades: Abbvie, Boeing, Oracle and Joby Aviation
India's Glenmark Pharma unit, Abbvie sign exclusive licensing pact
Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
Trump threatens impose up to 200% tariff on pharmaceuticals 'very soon'
How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
2 ETFs To Prepare You For A Potential Recession